$VAPO News

Last published 1mo ago

1mo agoCVRX NYXH VAPOCVRx Appoints John Landry as Chief Financial OfficerGlobeNewswireMINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
2y agoOTCM VAPOOTC Markets Group Welcomes Vapotherm, Inc. to OTCQXGlobeNewswireNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX:VAPO), a global
2y agoVAPOVapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQXPR NewswireVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has...
2y agoVAPOVapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXPR NewswireVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York...
2y agoVAPOVapotherm Educates over 8,000 Clinicians in Respiratory Care MonthPR NewswireVapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high...
3y agoVAPOVapotherm, Inc. (VAPO) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoVAPOVapotherm Reports Third Quarter 2023 Financial ResultsPR NewswireVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights. Third...
3y agoVAPOVapotherm To Report Third Quarter 2023 Financial ResultsPR NewswireVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023...
3y agoVAPOComputational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulasBusiness WireVapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of
3y agoVAPOThe FDA Approves IDE for ReGelTec's Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc DiseaseBusiness WireReGelTec, Inc., announced that the U.S. Food and Drug Administration has approved an IDE for the company's pivotal study to support premarket approval of its HYDRAFIL® System. The HYDRAFIL System contains an
3y agoVAPOPilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in childrenBusiness WireVapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of
3y agoVAPOVapotherm To Report Second Quarter 2023 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's
3y agoVAPOVapotherm Reports First Quarter 2023 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7
3y agoVAPOVapotherm Announces NYSE Continued Listing Standard Notice Related to Stock PriceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
3y agoVAPOVapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary Total revenue for the fourth quarter of 2022 was $18.7
3y agoVAPOVapotherm Announces Closing of $23 Million Private PlacementBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
3y agoVAPOVapotherm Announces $23 Million Private PlacementBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
3y agoVAPOVapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash BalanceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
3y agoEAR ITGR VAPOEargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority ShareholderGlobeNewswireSAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today
3y agoVAPOVapotherm Announces NYSE Continued Listing Standard Notice Related to Stock PriceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
3y agoVAPOVapotherm Announces Amendment to Debt AgreementBusiness Wire2023 Revenue Covenant tied to percentage of Company's annual operating plan and substantially waived if Company raises $15 million of new funding Liquidity Covenant reduced to $5 Million Option to pay a portion of
4y agoVAPOVapotherm Reports Third Quarter 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2022 financial results. Third Quarter 2022 Summary Total revenue for the third quarter of 2022 was $13.5 million, an increase
4y agoVAPOVapotherm to Report Third Quarter 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which
4y agoVAPOVapotherm Announces Debt Amendment and NYSE Continued Listing Standard NoticeBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
4y agoVAPOVapotherm to Participate in the Canaccord Genuity 42nd Annual Growth ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
4y agoVAPOVapotherm Reports Second Quarter 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the second quarter of 2022 was $13.0 million, a decrease of 37.1% over the second q
4y agoVAPOVapotherm to Report Second Quarter 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages s
4y agoVAPOVapotherm to Participate in the William Blair 42nd Annual Growth Stock ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
4y agoVAPOVapotherm Reports First Quarter 2022 Financial ResultsBusiness WireRevenue of $21.6 Million In-Line with Preliminary Revenue of $20.5 Million to $21.5 Million Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2022 financial results. First Quarter 2022 Summary Total re
4y agoVAPOVapotherm to Report First Quarter 2022 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages s
4y agoVAPOVapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual GuidanceBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and
4y agoVAPOVapotherm Launches Strategic Partnership with Carnegie Mellon University to Deliver a Tailored Artificial Intelligence (AI) Program to Drive Better Outcomes for Patients Suffering from Chronic Respiratory DiseasesBusiness WireVapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on developing innovative, non-invasive technologies and digital health solutions for respiratory patients, today announced a strategic partnership with Carnegie Mellon University,
4y agoVAPOVapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsBusiness Wire2021 Revenue of $113.3 Million Reflects Two-Year Compounded Annual Growth Rate of 53% Results in Line with Preliminary Revenue of $112.8 Million Worldwide Installed Base of Precision Flow Hi-VNI® Systems Now 35,200 New Debt Facility Provides U
4y agoVAPOVapotherm to Report Fourth Quarter and Full Year 2021 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic o
4y agoVAPOVapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic
4y agoVAPOVapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
5y agoVAPOVapotherm Reports Third Quarter 2021 Financial ResultsBusiness WireDisposables revenue increased 66.2% over the third quarter of 2020 Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company, today announced third quarter 2021 financial results. Third Quarter 2021 Summary
5y agoVAPOVapotherm to Report Third Quarter 2021 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages s
5y agoVAPOVapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production CapacityBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addit
5y agoVAPOVapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation PlatformBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is designed to provide high velocity therapy using an integra
5y agoVAPOVapotherm Reports Second Quarter 2021 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages
5y agoVAPOVapotherm to Participate in the Canaccord Genuity 41st Annual Growth ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
5y agoVAPOVapotherm to Report Second Quarter 2021 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages s
5y agoVAPOVapotherm to Host First Investor DayBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
5y agoVAPOVapotherm to Participate in the William Blair 41st Annual Growth Stock ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
5y agoVAPOVapotherm to Participate in the Bank of America Securities 2021 Health Care ConferenceBusiness WireVapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages
5y agoVAPOVapotherm Reports First Quarter 2021 Financial ResultsBusiness WireFirst Quarter 2021 Revenue of $32.3 Million Reflects 69% Increase Over Prior Year Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vap
5y agoVAPOVapotherm, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 5, 2021 / Vapotherm, Inc. (NYSE:VAPO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a replay o
5y agoVAPOVapotherm to Report First Quarter 2021 Financial ResultsBusiness WireVapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages s
5y agoVAPOVapotherm Reports Fourth Quarter and Fiscal Year 2020 Financial ResultsBusiness WireEXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat Patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2020 financial results.